Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

SABCS 2022 | STEAP1 targeting CAR-T therapy for solid tumors

Jon Amund Kyte, MD, PhD, University of Oslo, Oslo, Norway, discusses the development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer. STEAP1 is highly expressed in prostate cancer, Ewing sarcoma, amongst other cancers and is considered an attractive target due to low expression in normal tissue, apart from the non-vital prostate gland. The STEAP1-targeting CAR-T was evaluated in vivo in both subcutaneous and metastatic xenograft mouse models of prostate cancer and is currently being developed for a clinical trial for the treatment of Ewing sarcoma. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.